On November 8, 2022 Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, reported that updated clinical data from its MAGE-A4 franchise (Press release, Adaptimmune, NOV 8, 2022, View Source [SID1234623452]). Clinical data continue to support the potential of Adaptimmune’s engineered T-cell therapies for people with cancer across multiple solid tumor indications . The company will provide further details on a call to be held today, November 8, 2022, at 8:00 a.m. EST (1:00 p.m. GMT) during which management will be available for Q&A.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data in the SURPASS trial continue to demonstrate the potential of our next-generation cell therapy targeting MAGE-A4 in a broad range of difficult-to-treat, late-stage solid tumors," said Elliot Norry, Adaptimmune’s Chief Medical Officer. "We are initiating a Phase 2 trial, SURPASS-3, for people with ovarian cancer in collaboration with The GOG Foundation, Inc. I am pleased to announce that we recently received FDA RMAT Designation for ADP-A2M4CD8 for the treatment of patients with platinum resistant ovarian cancer. We also plan to gather data in urothelial and head & neck cancers with two additional cohorts that will focus on earlier lines of treatment. Finally, we will evaluate further development opportunities in the ongoing signal finding Phase 1 SURPASS trial in both monotherapy as well as in combination with the checkpoint inhibitor nivolumab."
New positive data reported in the Phase 1 SURPASS trial
Since data were reported at ESMO (Free ESMO Whitepaper) in September, there have been additional clinical responses including a new complete response in urothelial cancer and one new response in ovarian cancer
The objective response rate (ORR) has increased to 52% in heavily pre-treated patients with late -stage ovarian, urothelial, and head & neck cancers after a single dose of ADP-A2M4CD8 (ORR of 44% reported at ESMO (Free ESMO Whitepaper))
The overall ORR has increased to 37% (ORR of 33% reported at ESMO (Free ESMO Whitepaper))
Increased ORR in ovarian cancer to 43% (ORR of 36% reported at ESMO (Free ESMO Whitepaper))
Increased ORR in urothelial cancer to 57% (ORR of 43% reported at ESMO (Free ESMO Whitepaper))
There have been no new responses reported in head & neck cancer since the last update of 3 out of 4 patients responding as presented at ESMO (Free ESMO Whitepaper)
Durability continues to increase in this ongoing trial and is now at a median of ~20 weeks; previously reported as ~12 weeks at ESMO (Free ESMO Whitepaper)
Development plans for the SURPASS family of trials
The Phase 1 signal finding SURPASS trial is ongoing in both a monotherapy and a combination cohort evaluating ADP-A2M4CD8 with nivolumab (a checkpoint inhibitor)
Adaptimmune is working with The GOG Foundation, Inc and has initiated a Phase 2 trial (SURPASS-3) evaluating ADP-A2M4CD8 in both monotherapy and in combination with nivolumab in platinum-resistant ovarian cancer
The Company recently received FDA RMAT Designation for ADP-A2M4CD8 for the treatment of patients with platinum resistant ovarian cancer
The Company plans to pursue two new cohorts in the SURPASS Phase 1 trial with ADP–A2M4CD8
In combination with a checkpoint inhibitor in a second-line setting for advanced urothelial cancer
In combination with a checkpoint inhibitor in the first-line setting for advanced head & neck cancer
Conference Call Information
The Company will host a live teleconference and webcast to provide additional details at 8:00 a.m. EST (1:00 p.m. GMT) today, November 8, 2022. A live webcast of the conference call and replay can be accessed at View Source Call in information is as follows: (800)- 319-4610 (US or Canada) or +1 (416)- 915-3239 (International and additional options available HERE).